C3 signs $1m contract with CSL

Perth-based burns treatment company Clinical Cell Culture Ltd has entered into a supply agreement with pharmaceutical company CSL Ltd for the supply of Trypsin, a key component of the Company's ReCell tissue harvesting device.

Under the terms of the agreement, C3 has committed to a minimum quantity of Trypsin from CSL over a 2 year period, resulting in a financial commitment of $1 million.

C3 chief executive Bob Atwill said he was delighted that the supply of Trypsin had been secured with CSL, Australia's leading biopharmaceutical company.

"This agreement locks in the supply of enhanced formulations of Trypsin and the minimum purchase quantity reflects the anticipated increase in ReCell sales in the next 2 years."

"We have worked with CSL for a number of years and we look forward to developing our relationship in the supply of this key component," said Mr Atwill.